PROOVSTATION
3.3.2020 17:21:11 CET | Business Wire | Press release
ProovStation and GCA, a major European actor in the transport and industrial logistics sector, signed today a partnership with the aim of creating commercial synergies and supporting the development of the solutions offered by ProovStation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005747/en/
The aim of this agreement is to install 30 stations in all the automotive logistic sites of the Groupe Charles André. The deployment will start in April with the installation of the first 2 stations at Corbas (Lyon) and Fleury Merogis (Paris) sites.
For Serge Agneray, Director General of GCA Automotive Logistics division, this new equipment is part of their desire to find innovative solutions with added value for their customers.
GCA's Automotive Logistic branch, in strong growth, is composed of 32 sites in Europe. GCA offers many services to manufacturers, rental companies and vehicle sellers (new and used): transport (with 3.2 million vehicles per year), storage, preparation, maintenance, remarketing, 3D photo, and soon the automated inspection through the solution of ProovStation.
Thanks to their advanced Artificial Intelligence system, ProovStation gantries will allow GCA to offer a fully automated vehicle inspection in 3 seconds. During the passage of the car under the gantry, scratches of the order of a millimeter can be detected, which increases the precision and reduces the cost linked to the inspection.
“We are glad to count GCA as one of our trusted partners and we are looking forward to start this great collaboration which constitutes an important stage in our development. Furthermore, supporting in its activity a key player in the sector such as GCA, is a great recognition for our solution. It brings us closer to our goal, which is: make ProovStation the international standard for the car inspection” says Cédric BERNARD, CEO of ProovStation.
Delphine André, CEO of GCA adds "We are delighted to establish this partnership with ProovStation, a Start Up that shifts the lines in a profession in profound change, and will allow us to benefit our customers from innovative solutions that are always more efficient"
Last January, the Start Up announced its first commercial agreement with BCA Group, the European leader in used vehicle remarketing, aiming to deploy 40 inspection gantries, across Europe, in 13 countries. With this new contract, ProovStation further confirms the strong legitimacy and value of its vehicle inspection solution for the automotive industry.
ABOUT PROOVSTATION
ProovStation is a Deeptech Start Up specialized in Computer Vision. Its ambition is to industrialize, automate and standardize the global automotive inspection process. It reduces the total cost of car inspection and increase the efficiency of the whole process to improve the client and collaborator experience. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. This approach allows to cover all the angles and to capture all damages with an accuracy of one millimeter. The gantry identifies, quantifies and localizes all damages present on the vehicle through its Artificial Intelligence. It delivers a time stamped, geo-located and secured report via the Block Chain. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
ABOUT GCA
Founded in 1932, and currently leaded by Delphine André, granddaughter of its founder, Groupe Charles André (GCA) has developed and diversified its historical activities as road transporter of dangerous good. GCA is now able to intervene on the entire Supply chain in fields like aeronautics, food, automotive, Construction and minerals, chemistry, defense, energy, environment, rail and urban logistics. In 2019, GCA achieved a turnover of 1.4 Billion euros. In 15 countries, GCA employs over 9,400 people. GCA cultivates the values of autonomy, respect for commitments, humility and teamwork. The company attaches great importance to safety, quality of its human resources and training.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005747/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom